Amyris (AMRS) Shares Gap Up to $3.95
Amyris Inc (NASDAQ:AMRS)’s share price gapped up before the market opened on Wednesday . The stock had previously closed at $4.49, but opened at $3.95. Amyris shares last traded at $4.25, with a volume of 100180 shares changing hands.
A number of brokerages have weighed in on AMRS. HC Wainwright set a $11.00 target price on shares of Amyris and gave the company a “buy” rating in a research note on Tuesday, February 5th. BidaskClub raised shares of Amyris from a “sell” rating to a “hold” rating in a research note on Monday, January 7th. Finally, Zacks Investment Research downgraded shares of Amyris from a “hold” rating to a “sell” rating in a research note on Thursday, January 3rd. One investment analyst has rated the stock with a sell rating, one has given a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $8.83.
The stock has a market cap of $264.02 million, a price-to-earnings ratio of -1.61 and a beta of 0.29.
Several institutional investors and hedge funds have recently made changes to their positions in the stock. Wells Fargo & Company MN raised its stake in shares of Amyris by 50.6% in the 3rd quarter. Wells Fargo & Company MN now owns 41,903 shares of the biotechnology company’s stock valued at $333,000 after acquiring an additional 14,075 shares in the last quarter. JPMorgan Chase & Co. raised its stake in shares of Amyris by 96.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 446,909 shares of the biotechnology company’s stock valued at $3,548,000 after acquiring an additional 219,081 shares in the last quarter. Bank of New York Mellon Corp raised its stake in shares of Amyris by 8.6% in the 3rd quarter. Bank of New York Mellon Corp now owns 115,388 shares of the biotechnology company’s stock valued at $916,000 after acquiring an additional 9,172 shares in the last quarter. BlackRock Inc. raised its stake in shares of Amyris by 32.8% in the 3rd quarter. BlackRock Inc. now owns 2,277,432 shares of the biotechnology company’s stock valued at $18,082,000 after acquiring an additional 562,877 shares in the last quarter. Finally, GSA Capital Partners LLP bought a new position in shares of Amyris in the 3rd quarter valued at approximately $512,000. 36.69% of the stock is owned by institutional investors.
COPYRIGHT VIOLATION NOTICE: “Amyris (AMRS) Shares Gap Up to $3.95” was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece of content on another publication, it was illegally copied and reposted in violation of U.S. and international copyright & trademark laws. The legal version of this piece of content can be accessed at https://www.thecerbatgem.com/2019/04/17/amyris-amrs-shares-gap-up-to-3-95.html.
Amyris Company Profile (NASDAQ:AMRS)
Amyris, Inc, an integrated renewable products company, delivers alternatives to petroleum, plant, and animal-based products across a range of consumer and industry segments worldwide. It applies its bioscience solutions to convert plant sugars into hydrocarbon molecules, specialty ingredients, and consumer products.
Featured Story: What is the outlook for the FAANG stocks?
Receive News & Ratings for Amyris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris and related companies with MarketBeat.com's FREE daily email newsletter.